[{"from": "human", "value": "Could you give me a brief overview of this molecule? [C][C][Branch1][C][C][Branch2][=Branch1][C][C][C][C][N][Branch1][Branch1][C][C][Ring1][=Branch1][C][C][=C][C][=Branch1][=Branch2][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][F][C][=Branch1][S][=N][C][=Branch1][Ring2][=N][Ring1][#Branch2][N][C][C][O][C][C][Ring1][=Branch1][C][=C][C][=Branch1][#Branch2][=C][Branch1][Branch1][N][=C][Ring1][=Branch1][O][C][N][S][=Branch1][C][=O][=Branch1][C][=O][C][O]"}, {"from": "gpt", "value": "The molecule is an orally available selective inhibitor of the delta form of phosphatidylinositol 3-kinase (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta), with potential antineoplastic activity. Upon oral administration linperlisib selectively binds to and inhibits PI3K-delta and prevents the activation of the PI3K/AKT signaling pathway. This decreases proliferation of and induces cell death in PI3K-delta over-expressing tumor cells. PI3K-delta also plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of certain hematologic cancer cells. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells, thereby minimizing serious side effects."}]